Piper Sandler Maintains Abivax S.A.(ABVX.US) With Buy Rating, Maintains Target Price $42

Piper Sandler analyst Christopher Raymond maintains $Abivax S.A.(ABVX.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 52.3%

Moomoo NewsJul 16 08:33 ET · Ratings

LifeSci Capital Maintains Abivax S.A.(ABVX.US) With Buy Rating, Maintains Target Price $36

LifeSci Capital analyst Sam Slutsky maintains $Abivax S.A.(ABVX.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate of 47.9% and

Moomoo NewsJul 16 07:31 ET · Ratings

BTIG Maintains Abivax S.A.(ABVX.US) With Buy Rating, Maintains Target Price $43

BTIG analyst Julian Harrison maintains $Abivax S.A.(ABVX.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 56.3% and a total

Moomoo NewsJul 16 06:34 ET · Ratings

Abivax Provides Operational and Key Program Update

Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results

GlobeNewswireJul 15 16:00 ET

AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday.Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading after the compa

BenzingaJun 17 07:41 ET

Abivax S.A. | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementJun 4 16:56 ET · Announcements